References
- Laurell CB, Rannevik GA. Comparison of plasma protein changes induced by danazol, pregnancy, and estrogens. J Clin Endocrinol Metab 1979; 49: 719–25
- Thorell JI, Dymling JF, Rannevik G. Effect of danazol on thyroid functions in women. Postgrad Med J 1979; 55: 33–6
- Graham RL, Gambrell RD, Jr. Changes in thyroid function tests during danazol therapy. Obstet Gynecol 1980; 55: 395–7
- Panidis DK, Matalliotakis IM, Vayonas MD, et al. TRH test before, during and after long-term danazol treatment in patients with endometriosis. Hum Reprod 1989; 4: 903–5
- Pittaway DE, Fayez JA. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46: 790–5
- Takahashi K, Yamane Y, Kijima S, et al. CA 125 antigen is an effective diagnostic for external endometriosis. Gynecol Obstet Invest 1987; 23: 257–60
- Dawood MY, Khan-Dawood FS, Ramos J. Plasma and peritoneal fluid levels of CA125 in women with endometriosis. Am J Obstet Gynecol 1988; 159: 1526–31
- Tanaka T, Mizuno K, Umesaki N, et al. Changes in serum antiendometrial autoantibodies in endometriotic patients treated with Keishi-bukuryogan. J Trad Med 1997; 14: 442–3
- Tanaka T, Mizuno K, Umesaki N, et al. A preliminary immunopharmacological study of an antiendometriotic herbal medicine, Keishibukuryo-gan. Osaka City Med J 1988; 44: 117–24
- Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia-Oceania J Obstet Gynecol 1990; 16: 1–12
- Takebayashi T, Fujino Y, Umesaki N, et al. Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma. Preliminary study. Gynecol Obstet Invest 1995; 39: 207–11